Literature DB >> 26005519

Inhibitors of the PD-1/PD-L1 Pathway Can Mobilize the Immune System: An Innovative Potential Therapy for Cancer and Chronic Infections.

Ahmed F Abdel-Magid1.   

Abstract

Entities:  

Year:  2015        PMID： 26005519      PMCID： PMC4434459          DOI： 10.1021/acsmedchemlett.5b00148

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.345


× No keyword cloud information.
  4 in total

Review 1.  The PD-1/PD-L1 pathway in human pathology.

Authors:  M Saresella; V Rainone; N M Al-Daghri; M Clerici; D Trabattoni
Journal:  Curr Mol Med       Date:  2012-03       Impact factor: 2.222

Review 2.  Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway.

Authors:  Kim C Ohaegbulam; Amer Assal; Eszter Lazar-Molnar; Yu Yao; Xingxing Zang
Journal:  Trends Mol Med       Date:  2014-10-30       Impact factor: 11.951

Review 3.  The PD-1/PD-L1 pathway: biological background and clinical relevance of an emerging treatment target in immunotherapy.

Authors:  Simone Muenst; Savas D Soysal; Alexandar Tzankov; Sylvia Hoeller
Journal:  Expert Opin Ther Targets       Date:  2014-12-10       Impact factor: 6.902

Review 4.  Costimulatory molecule programmed death-1 in the cytotoxic response during chronic hepatitis C.

Authors:  Juan-Ramón Larrubia; Selma Benito-Martínez; Joaquín Miquel; Miryam Calvino; Eduardo Sanz-de-Villalobos; Trinidad Parra-Cid
Journal:  World J Gastroenterol       Date:  2009-11-07       Impact factor: 5.742
  4 in total
  9 in total

Review 1.  The Next Generation of Immunotherapy for Cancer: Small Molecules Could Make Big Waves.

Authors:  William G Kerr; John D Chisholm
Journal:  J Immunol       Date:  2019-01-01       Impact factor: 5.422

2.  Hepatitis B core antigen upregulates B7-H1 on dendritic cells by activating the AKT/ERK/P38 pathway: a possible mechanism of hepatitis B virus persistence.

Authors:  Man Li; Zhen-Hua Zhou; Xue-Hua Sun; Xin Zhang; Xiao-Jun Zhu; Shu-Gen Jin; Ya-Ting Gao; Yun Jiang; Yue-Qiu Gao
Journal:  Lab Invest       Date:  2016-09-12       Impact factor: 5.662

3.  Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.

Authors:  Silvia Darb-Esfahani; Catarina Alisa Kunze; Hagen Kulbe; Jalid Sehouli; Stephan Wienert; Judith Lindner; Jan Budczies; Michael Bockmayr; Manfred Dietel; Carsten Denkert; Ioana Braicu; Korinna Jöhrens
Journal:  Oncotarget       Date:  2016-01-12

Review 4.  PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?

Authors:  Zijun Y Xu-Monette; Mingzhi Zhang; Jianyong Li; Ken H Young
Journal:  Front Immunol       Date:  2017-12-04       Impact factor: 7.561

5.  Prognostic value of PD -L1 expression in patients with primary solid tumors.

Authors:  Xiao Xiang; Peng-Cheng Yu; Di Long; Xiao-Li Liao; Sen Zhang; Xue-Mei You; Jian-Hong Zhong; Le-Qun Li
Journal:  Oncotarget       Date:  2017-12-22

6.  Therapeutic targeting of PD-1/PD-L1 blockade by novel small-molecule inhibitors recruits cytotoxic T cells into solid tumor microenvironment.

Authors:  Rita C Acúrcio; Sabina Pozzi; Barbara Carreira; Marta Pojo; Nuria Gómez-Cebrián; Sandra Casimiro; Adelaide Fernandes; Andreia Barateiro; Vitor Farricha; Joaquim Brito; Ana Paula Leandro; Jorge A R Salvador; Luís Graça; Leonor Puchades-Carrasco; Luís Costa; Ronit Satchi-Fainaro; Rita C Guedes; Helena F Florindo
Journal:  J Immunother Cancer       Date:  2022-07       Impact factor: 12.469

7.  The prevalence and clinicopathological features of programmed death-ligand 1 (PD-L1) expression: a pooled analysis of literatures.

Authors:  Ziying Lin; Yutong Xu; Yaxiong Zhang; Qihua He; Jianrong Zhang; Jianxing He; Wenhua Liang
Journal:  Oncotarget       Date:  2016-03-22

8.  Computational Insight Into the Small Molecule Intervening PD-L1 Dimerization and the Potential Structure-Activity Relationship.

Authors:  Danfeng Shi; Xiaoli An; Qifeng Bai; Zhitong Bing; Shuangyan Zhou; Huanxiang Liu; Xiaojun Yao
Journal:  Front Chem       Date:  2019-11-12       Impact factor: 5.221

9.  A pH-responsive Pickering Nanoemulsion for specified spatial delivery of Immune Checkpoint Inhibitor and Chemotherapy agent to Tumors.

Authors:  Le Jia; Minghui Pang; Man Fan; Xuan Tan; Yiqian Wang; Menglin Huang; Yijing Liu; Qin Wang; Yanhong Zhu; Xiangliang Yang
Journal:  Theranostics       Date:  2020-08-07       Impact factor: 11.556
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.